2. Disease Areas
  3. Cancer Urogenital Disease
  4. Prostate Cancer Urogenital Cancer
  5. Metastatic Prostate Cancer

Metastatic Prostate Cancer

Metastatic prostate cancer refers to the spread of prostate cancer beyond the prostate gland to other parts of the body, most commonly to lymph nodes and bones, and less frequently to organs such as the lungs. It is also known as advanced prostate cancer.

Metastatic Prostate Cancer (6):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-45661
    Inixaciclib 2370913-42-9 99.93%
    Inixaciclib (NUV-422) is a blood-brain barrier-penetrant inhibitor of CDK2, CDK4 and CDK6. Inixaciclib inhibits cancer cell growth. Inixaciclib induces anti-tumor activity in xenograft models of glioblastoma, CDK4/CDK6 inhibitor-resistant HR+ HER2- metastatic breast cancer, and anti-androgen-resistant prostate cancer. Inixaciclib can be used for the research of relapsed or metastatic castration-resistant prostate cancer.
    Inixaciclib
  • HY-173186
    TLK1-IN-1
    TLK1-IN-1 is a TLK1B inhibitor with a human IC50 of 7.2 μM. TLK1-IN-1 causes accumulation of DNA damage and induces apoptotic cell death in cancer cells. TLK1-IN-1 can be used for the research of metastatic castration-resistant prostate cancer.
    TLK1-IN-1
  • HY-123664
    Trioxifene mesylate 68307-81-3
    Trioxifene mesylate (LY133314) is an orally active and selective estrogen receptor (ER) modulator with human ERα IC50 of 203.49 nM and Ki of 20.84 nM. Trioxifene mesylate binds estradiol receptors, inhibits ERα-mediated gene expression, reduces circulating gonadotrophin levels. Trioxifene mesylate can be used for the research of advanced breast cancer and androgen-independent, metastatic prostatic adenocarcinoma.
    Trioxifene mesylate
  • HY-184006
    BMX ligand-1 1863114-58-2
    BMX ligand-1 (Compound 9) is a BMX ligand. BMX ligand-1 serves as a target protein ligand for the synthesis of BMX PROTAC degraders, such as IHMT-BMX-068 (HY-184005). BMX ligand-1 is applicable to prostate cancer research.
    BMX ligand-1
  • HY-135529
    Trioxifene 63619-84-1
    Trioxifene (LY133314 free base) is an orally active and selective estrogen receptor (ER) modulator with human ERα IC50 of 203.49 nM and Ki of 20.84 nM. Trioxifene binds estradiol receptors, inhibits ERα-mediated gene expression, reduces circulating gonadotrophin levels. Trioxifene can be used for the research of advanced breast cancer and androgen-independent, metastatic prostatic adenocarcinoma.
    Trioxifene
  • HY-183273
    BRD4/AKT-IN-1 3087270-50-3
    BRD4/AKT-IN-1 is a BRD4/AKT inhibitor with BRD4 IC50 66.12 nM and AKT1 IC50 143.81 nM. BRD4/AKT-IN-1 blocks BRD4-mediated c-Myc transcriptional regulation, modulates AKT1 signaling, decouples AKT phosphorylation from pro-survival effectors. BRD4/AKT-IN-1 induces G0/G1 cell cycle arrest via downregulated phosphorylated RB, cyclin E1, CDK2. BRD4/AKT-IN-1 elevates LC3B levels to promote autophagy. BRD4/AKT-IN-1 promotes apoptosis in cancer cells. BRD4/AKT-IN-1 can be used for the research of metastatic castration-resistant prostate cancer.
    BRD4/AKT-IN-1